Putrescine

Putrescine

SCHEMBL29458

Cl.Cl.NCCCCN

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Putrescine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1995 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
US-20260085292-A1 MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS UNIV NORTHWESTERN (US) 2026-03-26 US claimed
EP-4709842-A1 SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS Nuwacell Biotechnologies Co., Ltd. (CN) 2026-03-18 EP claimed
US-12378529-B2 Method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents GENEX HEALTH CO., LTD (CN) 2025-08-05 US claimed
EP-4584365-A2 MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS Northwestern University (US) 2025-07-16 EP claimed
US-12359173-B2 Serum-free and xeno-free culture medium for expanding mesenchymal stem cells NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) 2025-07-15 US claimed
CN-120005806-A CHO cell culture medium and application thereof 江苏埃美益生物技术有限公司 2025-05-16 CN claimed
CN-119020290-B Serum replacement, culture medium and application thereof in tumor organoid culture 山东伯桢生物科技有限公司 2025-05-13 CN claimed
WO-2025019764-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS MATTERWORKS INC (US) 2025-01-23 WO claimed
CN-119286765-A Organoid basal medium and method for maintaining and promoting organoid growth 山东伯桢生物科技有限公司 2025-01-10 CN claimed
EP-1482031-A1 Serum-free mammalian cell culture medium, and uses thereof INVITROGEN CORPORATION (US) 2004-12-01 EP claimed
EP-1437133-A1 AMINES WITH ANTIALCOHOLIC AGENTS Garbil Pharma Investigacion Chile Ltda. (CL) 2004-07-14 EP claimed
WO-2003100026-A2 METHODS, COMPOSITIONS, AND GROWTH AND DIFFERENTIATION FACTORS FOR INSULIN-PRODUCING CELLS NOVOCELL, INC. (US) 2003-12-04 WO claimed
US-6423540-B2 CELL DIFFERENTIATION PROTEIN NESTEC S.A. (CH) 2002-07-23 US claimed
US-20020042129-A1 Immortalized human skin cell lines and novel serum-free medium useful for the production thereof NESTEC S.A. 2002-04-11 US claimed
US-20020012993-A1 IMPROVED IMMORTALIZED HUMAN SKIN CELL LINES AND NOVEL SERUM-FREE MEDIUM USEFUL FOR THE PRODUCTION THEREOF NESTEC SA (CH) 2002-01-31 US claimed
EP-0780469-B1 Immortalized human skin cell lines and serum-free medium for the production thereof NESTLE SA (CH) 2001-02-28 EP claimed
EP-0877797-A1 IMPROVED IMMORTALIZED HUMAN SKIN CELL LINES AND NOVEL SERUM-FREE MEDIUM USEFUL FOR THE PRODUCTION THEREOF SOCIETE DES PRODUITS NESTLE S.A. (CH) 1998-11-18 EP claimed
US-5232848-A Air-equilibrated, for in vitro mammalian cell culture, serum-free or supplemented W. R. GRACE & CO.-CONN. (US) 1993-08-03 US claimed
US-5135866-A Without supplemental serum or serum-derived proteins W. R. GRACE & CO.-CONN. (US) 1992-08-04 US claimed